Pollack et al. analyzed 68,495 primary cases of melanoma diagnosed from 1992 to 2005 and found a significant difference between melanoma-specific survival (MSS) by stage at diagnosis, concluding with a recommendation for early detection through screening those at risk for melanoma, thus applying to NF1 patients [85]. The gene discussed is NF1; the disease is melanoma.